Omeros

OMER

Market cap $278M

Overview Fund Activity

4.09 USD

-0.06

1.45%

At close Updated Sep 15, 4:00 PM EDT

Pre-market

After hours

4.09

0.00

0%

1 day

-1.45%

5 days

-3.08%

1 month

-7.26%

3 months

21.36%

6 months

-52%

Year to date

-58.43%

1 year

4.87%

5 years

-66.67%

10 years

-69.18%

About: Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.

Employees: 202

Healthcare Biotechnology

0

Funds holding %

of 7,463 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

29% more repeat investments, than reductions

Existing positions increased: 45 | Existing positions reduced: 35

2.04% more ownership

Funds ownership: 47.57% [Q1] → 49.61% (+2.04%) [Q2]

7% less funds holding

Funds holding: 136 [Q1] → 126 (-10) [Q2]

36% less first-time investments, than exits

New positions opened: 16 | Existing positions closed: 25

55% less call options, than puts

Call options by funds: $1.44M | Put options by funds: $3.19M

62% less capital invested

Capital invested by funds: $227M [Q1] → $87.2M (-$139M) [Q2]

See Fund Rankings

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target

$36

780% upside

Avg. target

$36

780% upside

High target

$36

780% upside

1 analyst rating

1 positive

100%

0 neutral

0%

0 negative

0%

D. Boral Capital

Jason Kolbert

$36

Buy

Maintained

3 Sep 2025

See Analyst Rankings

Financial journalist opinion

Omeros Announces Publication Highlighting Survival Outcomes in TA-TMA Patients Treated with Narsoplimab Under Its Global Expanded Access Program

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced the publication of a peer-reviewed manuscript in the American Journal of Hematology detailing survival outcomes in adult and pediatric patients with life-threatening transplant-associated thrombotic microangiopathy (TA-TMA) treated with narsoplimab through a global expanded access program (EAP). Narsoplimab inhibits MASP-2, the effector enzyme of the lectin pathway of complement, and is currently under review for market.

Omeros Announces Publication Highlighting Survival Outcomes in TA-TMA Patients Treated with Narsoplimab Under Its Global Expanded Access Program

Omeros Corporation (OMER) Q2 2025 Earnings Call Transcript

Omeros Corporation (NASDAQ:OMER ) Q2 2025 Earnings Conference Call August 14, 2025 4:30 PM ET Company Participants Catherine A. Melfi - Chief Regulatory Officer & VP of Regulatory Affairs and Quality Systems David J.

Omeros Corporation (OMER) Q2 2025 Earnings Call Transcript

Omeros Corporation Reports Second Quarter 2025 Financial Results

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced recent highlights and developments as well as financial results for the second quarter ended June 30, 2025, which include: Net loss for the second quarter of 2025 was $25.4 million, or $0.43 per share, compared to a net loss of $56.0 million, or $0.97 per share for the second quarter of 2024. For the six months ended June 30, 2025, our net loss was $58.9 million, or $1.01 per share, compared to a net loss of $93.2 milli.

Omeros Corporation Reports Second Quarter 2025 Financial Results

Omeros Corporation to Announce Second Quarter Financial Results on August 14, 2025

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its financial results for the quarter ended June 30, 2025, on Thursday, August 14, 2025, after the market closes. Omeros management will host a conference call and webcast that same day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results as well as recent developments and highlights. Conference Call Details For online access to the live webcast of the conferen.

Omeros Corporation to Announce Second Quarter Financial Results on August 14, 2025

Omeros Corporation Announces Pricing of $22 Million Registered Direct Offering

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) (“Omeros” or the “Company”) announced that on July 24, 2025 it entered into a securities purchase agreement with Polar Asset Management Partners to sell approximately $22 million of its common stock in a registered direct offering. Under the terms of the securities purchase agreement, the Company has agreed to sell 5,365,853 shares of its common stock at a price of $4.10 per share, which represents a premium of approximately 14% to the.

Omeros Corporation Announces Pricing of $22 Million Registered Direct Offering

Omeros Submits Narsoplimab Marketing Authorization Application to the European Medicines Agency for the Treatment of TA-TMA

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced the recent submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). The MAA includes response-based analyses in narsoplimab-treated TA-TMA patients as well as analyses comparing overall survival between narsoplimab-treated patients and a well-matched external con.

Omeros Submits Narsoplimab Marketing Authorization Application to the European Medicines Agency for the Treatment of TA-TMA

Omeros Announces Webcast Details for Annual Meeting of Shareholders

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced that the company will host a live webcast of its Annual Meeting of Shareholders, which will be held virtually on Friday, June 27, 2025, starting at 10:00 a.m. Pacific Time. The live webcast can be accessed through the virtual shareholder meeting website at www.virtualshareholdermeeting.com/OMER2025. A general corporate overview and question-and-answer session will follow the business portion of the annual meeting. As de.

Omeros Announces Webcast Details for Annual Meeting of Shareholders

Omeros Analyst Sees $1 Billion Potential For Narsoplimab Before FDA Decision

H.C. Wainwright analyst Brandon Folkes initiated coverage on Omeros Corporation OMER with a Buy rating and a price forecast of $9.

Omeros Analyst Sees $1 Billion Potential For Narsoplimab Before FDA Decision

Zacks Investment Research

Down 54.8% in 4 Weeks, Here's Why You Should You Buy the Dip in Omeros (OMER)

Omeros (OMER) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Down 54.8% in 4 Weeks, Here's Why You Should You Buy the Dip in Omeros (OMER)

Omeros: On The Brink As It Awaits Its Fall PDUFA For A Potential Blockbuster

Omeros' recent convertible note exchange highlights severe liquidity issues and questionable creditworthiness, leading to a sharp stock decline. Despite reducing near-term debt obligations, Omeros faces a significant cash burn, with only $52.5 million in cash as of March 2025. The company's cash runway is dangerously short, likely lasting only until late summer 2025, necessitating urgent financial action.

Omeros: On The Brink As It Awaits Its Fall PDUFA For A Potential Blockbuster

See News Rankings

Charts implemented using Lightweight Charts™